A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 6, 2019

Primary Completion Date

March 11, 2020

Study Completion Date

May 5, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

MSTT1041A

Participants will receive subcutaneous (SC) MSTT1041A

DRUG

Placebo

Participants will receive SC placebo

Trial Locations (21)

32789

Florida Pulmonary Research Institute, LLC, Winter Park

33136

South Coast Research Center, Inc., Miami

33162

Harmony Clinical Research, Inc, North Miami Beach

33624

Forward Clinical Trials, Tampa

33702

GCP Global Clinical Professionals, St. Petersburg

35209

Alabama Allergy & Asthma, Birmingham

40241

Dermatology Specialists Research, LLC, Louisville

48149

Universitatsklinikum Munster, Münster

61761

Midwest Sinus Allergy and Asthma - CRN, Normal

74136

Vital Prospects Clinical Research Institute PC - CRN, Tulsa

77004

Center for Clinical Studies, Houston

80907

Asthma & Allergy; Associates, P.C., Colorado Springs

89119

Clinical Research Consortium Nevada, Las Vegas

90025

California Allergy and Asthma Medical Group - CRN, Los Angeles

Jonathan Corren MD, Inc., Los Angeles

07601

Skin Laser and Surgery Specialists of New York and New Jersey LLC - Interspond - PPDS, Hackensack

30-033

Centrum Medyczne ALL-MED, Krakow

90-153

SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, Lodz

35-055

Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina; Klinika Dermatologii, Rzeszów

70-322

Laser Clinic, Szczecin

51-685

Wro Medica, Wroc?aw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT03747575 - A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter